Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Item
http://www.wikidata.org/entity/Q35125760
Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometryClinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors.Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.
P2860

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Item
http://www.wikidata.org/entity/Q35125760
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Intracellular and plasma pharm ...... iency virus-infected patients.
@ast
Intracellular and plasma pharm ...... iency virus-infected patients.
@en
type
label
Intracellular and plasma pharm ...... iency virus-infected patients.
@ast
Intracellular and plasma pharm ...... iency virus-infected patients.
@en
prefLabel
Intracellular and plasma pharm ...... iency virus-infected patients.
@ast
Intracellular and plasma pharm ...... iency virus-infected patients.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
Intracellular and plasma pharm ...... iency virus-infected patients.
@en
P2093
P2860
P304
P31
P356
10.1128/AAC.48.7.2388-2393.2004
P407
P433
P478
P577
P698
P932